Ocumension Therapeutics (1477.HK)
- Previous Close
6.000 - Open
6.000 - Bid 6.380 x --
- Ask 6.470 x --
- Day's Range
6.000 - 6.470 - 52 Week Range
4.510 - 10.400 - Volume
1,504,500 - Avg. Volume
596,325 - Market Cap (intraday)
4.488B - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.640 - Earnings Date Mar 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.58
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. The company offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, uveitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
www.ocumension.comRecent News: 1477.HK
Performance Overview: 1477.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1477.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1477.HK
Valuation Measures
Market Cap
4.49B
Enterprise Value
3.50B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.78
Price/Book (mrq)
1.42
Enterprise Value/Revenue
14.22
Enterprise Value/EBITDA
-10.93
Financial Highlights
Profitability and Income Statement
Profit Margin
-154.16%
Return on Assets (ttm)
-7.96%
Return on Equity (ttm)
-13.40%
Revenue (ttm)
246.37M
Net Income Avi to Common (ttm)
-379.79M
Diluted EPS (ttm)
-0.640
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05B
Total Debt/Equity (mrq)
4.72%
Levered Free Cash Flow (ttm)
--
Research Analysis: 1477.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 1477.HK
1477.HK does not have Company Insights